Views & Analysis Deep Dive: R&D Disruption With costs skyrocketing and return on investment plummeting, R&D arguably needs disruption more than any other area of the industry.
Views & Analysis Listen and support: How to conduct a patient-centric clinica... Clinical trial sponsors understand the value of patient-centric studies, but success relies on a time-consuming paradigm shift and progress is slow.
Views & Analysis Millendo’s Julia Owens on leadership in rare diseases Rare disease specialists Millendo Therapeutics are hoping their drug livoletide will become the first treatment for Prader-Willi syndrome.
Views & Analysis How digital is reversing fortunes in R&D A new report lays out the ways digital transformation could reverse the trend of declining ROI in pharma R&D.
Views & Analysis UK leaders: Takeda’s Jon Neal In the first of a new series where we talk to GMs of UK pharma divisions, managing director for Takeda UK & Ireland, Jon Neal, tells us about the Shire acquisition, rare diseases, a
Views & Analysis Q&A: Fortress Biotech’s Lindsay Rosenwald on breathing new l... One downside of the explosion in our knowledge about potential drug targets is that many promising candidates are getting left on the backburner.
News Dexcom is first to join FDA/CMS health tech pilot The FDA has named Dexcom as the first company to take part in its TEMPO pilot, which aims to bring digital health tech to patients more quickly.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
